Meta Cut 20 mg x 60 Capsules – Roger Pharma

Description

Roger Pharma Meta Cut is a premium research formulation combining SR-9009 (Stenabolic), GW-501516 (Cardarine), and Yohimbine into a single advanced investigational blend. Developed exclusively for laboratory research, this formulation enables scientists to investigate the interaction between REV-ERBα signaling, PPAR-δ activation, adrenergic receptor pathways, and metabolic physiology through complementary biological mechanisms.

By integrating SR-9009, a REV-ERBα (NR1D1) agonist, GW-501516, a selective Peroxisome Proliferator-Activated Receptor Delta (PPAR-δ) agonist, and Yohimbine, an investigational alpha-2 adrenergic receptor antagonist, Meta Cut provides researchers with a comprehensive platform for studying cellular energy metabolism, lipid metabolism, mitochondrial biology, adrenergic signaling, receptor pharmacology, and molecular endocrinology.

Each bottle contains 60 capsules, with a total strength of 20 mg per capsule, manufactured by Roger Pharma under stringent pharmaceutical-quality standards. Every batch undergoes comprehensive quality testing to ensure exceptional purity, formulation consistency, and dependable laboratory performance.

Key Features

• Premium multi-compound research formulation
• 20 mg per capsule
• 60 capsules per bottle
• Contains SR-9009 (Stenabolic)
• Contains GW-501516 (Cardarine)
• Contains Yohimbine
• Combines a REV-ERBα agonist, PPAR-δ agonist, and alpha-2 adrenergic receptor antagonist
• High-purity laboratory-grade formulation
• Suitable for investigations involving metabolic physiology, lipid metabolism, mitochondrial biology, adrenergic signaling, receptor pharmacology, and molecular endocrinology
• Manufactured under rigorous pharmaceutical-quality standards
• Intended exclusively for laboratory and scientific research applications

How It Works

Meta Cut combines three investigational compounds with complementary biological mechanisms, allowing researchers to investigate multiple molecular pathways involved in energy metabolism, cellular signaling, and metabolic regulation.

• SR-9009 (Stenabolic) selectively activates the REV-ERBα (NR1D1) nuclear receptor, enabling investigations into circadian biology, mitochondrial function, metabolic adaptation, and intracellular signaling.
• GW-501516 (Cardarine) acts as a selective PPAR-δ agonist, providing a research model for studying fatty acid oxidation, glucose metabolism, mitochondrial biogenesis, and cellular energy homeostasis.
• Yohimbine is investigated for its interaction with alpha-2 adrenergic receptors, making it valuable for research involving adrenergic signaling, neurotransmitter regulation, metabolic physiology, and receptor pharmacology.

Together, these complementary mechanisms provide researchers with a comprehensive platform for investigating REV-ERBα signaling, PPAR-δ biology, adrenergic receptor activity, mitochondrial physiology, energy metabolism, intracellular communication, and molecular endocrinology under controlled laboratory conditions.

This formulation is intended exclusively for laboratory and scientific research and is not intended for human consumption.

Contents

Active Ingredients (Per Capsule):

• SR-9009 (Stenabolic)
• GW-501516 (Cardarine)
• Yohimbine

Total Strength: 20 mg per Capsule

Packaging: 60 Capsules